B+
Bull case
20%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
NKTX
NkartaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Convincing activity in myositis and systemic sclerosis alongside manageable safety could support a sharp re-rating. Outpatient administration and the company-projected runway provide time for follow-up studies, but neither establishes durable efficacy.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Early Phase 1/2 open-label findings may not demonstrate durable benefit or predict later controlled outcomes. [#PR-2026-09-08]
Momentum
70
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.60 · Bull $3.00 · Bear $0.75Analysis 2026-10-22; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $10.83
Why
Momentum70 · Δ7d -
Value41 · Δ7d -0.1
Sentiment43 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Early Phase 1/2 open-label findings may not demonstrate durable benefit or predict later controlled outcomes. [#PR-2026-09-08]
- • Enrollment, manufacturing complexity, competition for patients, and dependence on NKX019 may delay development. [#PR-2026-09-08]
- • Small, open-label, dose-escalation datasets may show limited or non-durable benefit, safety concerns, or results too preliminary to support the valuation.
Catalyst clock
2026-11-08
NKX019 myositis data at ACR
Lead driver: Sentiment · See AI snapshot
Momentum
70
8% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
43
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 70.2 / Value 40.6 / Sentiment 42.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-22. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$128.21M
Beta
0.55
Shares Out
71.62M
P/E (TTM) · Derived
-1.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.41
Rev YoY
-100.0%
EPS YoY
+74.5%
Gross Margin
-
Op Margin
-
Net Debt
-$199.86M
Current Ratio
7.98
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data